Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Read More…
Industry, Sector and Symbol
Industry Hospital & medical service plans
Sub-IndustryManaged Health Care
SectorMedical
Phone502-580-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$56.91 billion
Profitability
Miscellaneous
Employees41,600
Next Earnings Date11/6/2019 (Confirmed)
OptionableOptionable
Humana (NYSE:HUM) Frequently Asked Questions
What is Humana's stock symbol?
Humana trades on the New York Stock Exchange (NYSE) under the ticker symbol "HUM."
How often does Humana pay dividends? What is the dividend yield for Humana?
Humana declared a quarterly dividend on Thursday, August 22nd. Shareholders of record on Monday, September 30th will be given a dividend of $0.55 per share on Friday, October 25th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.76%. The ex-dividend date of this dividend is Friday, September 27th. View Humana's Dividend History.
How will Humana's stock buyback program work?
Humana announced that its board has authorized a stock buyback plan on Friday, December 15th 2017, which allows the company to buyback $3,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Stock buyback plans are generally an indication that the company's board believes its stock is undervalued.
How were Humana's earnings last quarter?
Humana Inc (NYSE:HUM) released its quarterly earnings data on Wednesday, July, 31st. The insurance provider reported $6.05 earnings per share for the quarter, topping analysts' consensus estimates of $5.24 by $0.81. The insurance provider had revenue of $16.25 billion for the quarter, compared to analysts' expectations of $15.88 billion. Humana had a return on equity of 22.47% and a net margin of 4.13%. The firm's revenue for the quarter was up 13.9% compared to the same quarter last year. During the same period in the previous year, the business earned $3.96 EPS. View Humana's Earnings History.
When is Humana's next earnings date?
How can I listen to Humana's earnings call?
Humana will be holding an earnings conference call on Wednesday, November 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Humana issued on next quarter's earnings?
Humana issued an update on its FY19 earnings guidance on Wednesday, July, 31st. The company provided earnings per share guidance of $17.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $17.46.
What price target have analysts set for HUM?
20 Wall Street analysts have issued 12 month price targets for Humana's shares. Their predictions range from $275.02 to $415.00. On average, they anticipate Humana's stock price to reach $332.61 in the next twelve months. This suggests a possible upside of 14.7% from the stock's current price. View Analyst Price Targets for Humana.
What is the consensus analysts' recommendation for Humana?
20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Humana in the last year. There are currently 5 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Humana.
What are Wall Street analysts saying about Humana stock?
Here are some recent quotes from research analysts about Humana stock:
- 1. According to Zacks Investment Research, "Humana’s shares have lost year-to-date against its industry’s gain. Moreover, the company has witnessed its 2020 earnings estimates move south over the last 30 days. Its rising level of expenses since 2010 persistently weighs on the bottom line. The company expects high benefit expenses which will lead to an overall increase in operating expenses going forward. Also, increase in leverage might lead to heightened financial risk for the company and burden on margins. Nevertheless, it is well-poised for growth on the back of its strong Medicare business. Its top line has been witnessing an uptrend for the past several years. Acquisitions and dispositions made by the company have also led to business growth over the last few quarters." (4/11/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating on HUM shares and maintain our 12-month price target of $325. After the market close on the company reaffirmed its 2018 EPS guidance. The company also provided updated 2019 membership metrics. Given the update, we are increasing our 2019 revenue and EPS estimates. The company had previously indicated that it expected 2019 adjusted EPS to grow above its stated long-term goal of 11-15%. With its filing on Wednesday, the company did not comment on 2019 EPS guidance, but will provide detailed 2019 financial guidance when it reports 4Q18 and year-end 2018 results on Wednesday, February 6, 2019." (1/2/2019)
Has Humana been receiving favorable news coverage?
Media headlines about HUM stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Humana earned a daily sentiment score of -1.7 on InfoTrie's scale. They also gave press coverage about the insurance provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Humana.
Are investors shorting Humana?
Humana saw a drop in short interest in September. As of September 30th, there was short interest totalling 2,290,000 shares, a drop of 22.6% from the August 30th total of 2,960,000 shares. Based on an average daily trading volume, of 1,060,000 shares, the days-to-cover ratio is presently 2.2 days. Currently, 1.7% of the company's shares are short sold. View Humana's Current Options Chain.
Who are some of Humana's key competitors?
What other stocks do shareholders of Humana own?
Who are Humana's key executives?
Humana's management team includes the folowing people:
- Mr. Bruce Dale Broussard, Pres, CEO & Director (Age 57)
- Mr. Brian Andrew Kane, Chief Financial Officer (Age 46)
- Mr. Timothy S. Huval, Chief HR Officer (Age 53)
- Ms. Jody L. Bilney, Chief Consumer Officer (Age 58)
- Dr. William Kevin Fleming Pharm.D., PharmD, RPh, Segment Pres of Healthcare Services (Age 51)
Who are Humana's major shareholders?
Humana's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Calamos Advisors LLC (0.25%), Artemis Investment Management LLP (0.15%), Strs Ohio (0.10%), Nisa Investment Advisors LLC (0.05%), Zurcher Kantonalbank Zurich Cantonalbank (0.05%) and Rhenman & Partners Asset Management AB (0.04%). Company insiders that own Humana stock include Brian P Leclaire, Bruce D Broussard, Christopher H Hunter, Cynthia H Zipperle, David A Jr/Ky Jones, Elizabeth D Bierbower, Heidi S Margulis, Jody L Bilney, M Todoroff Christopher, Roy A Beveridge, Timothy Alan Wheatley, Timothy S Huval and William Kevin Fleming. View Institutional Ownership Trends for Humana.
Which institutional investors are selling Humana stock?
HUM stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Scout Investments Inc., Calamos Advisors LLC, Strs Ohio, Robeco Institutional Asset Management B.V., DNB Asset Management AS, Gateway Investment Advisers LLC and Meeder Asset Management Inc.. Company insiders that have sold Humana company stock in the last year include Brian P Leclaire, Christopher H Hunter, David A Jr/Ky Jones, Heidi S Margulis and Roy A Beveridge. View Insider Buying and Selling for Humana.
Which institutional investors are buying Humana stock?
HUM stock was bought by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, Zurcher Kantonalbank Zurich Cantonalbank, Envestnet Asset Management Inc., State of Alaska Department of Revenue, Scott & Selber Inc., Beech Hill Advisors Inc., Prospera Financial Services Inc and CHURCHILL MANAGEMENT Corp. View Insider Buying and Selling for Humana.
How do I buy shares of Humana?
Shares of HUM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Humana's stock price today?
One share of HUM stock can currently be purchased for approximately $290.11.
How big of a company is Humana?
Humana has a market capitalization of $39.19 billion and generates $56.91 billion in revenue each year. The insurance provider earns $1.68 billion in net income (profit) each year or $14.55 on an earnings per share basis. Humana employs 41,600 workers across the globe.View Additional Information About Humana.
What is Humana's official website?
How can I contact Humana?
Humana's mailing address is 500 West Main Street, LOUISVILLE KY, 40202. The insurance provider can be reached via phone at 502-580-1000 or via email at [email protected]
MarketBeat Community Rating for Humana (NYSE HUM)
MarketBeat's community ratings are surveys of what our community members think about Humana and other stocks. Vote "Outperform" if you believe HUM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HUM will underperform the S&P 500 over the long term. You may vote once every thirty days.
